Deals of the month - Glaxosmithkline

Rare issuer GlaxoSmithKline has made a storming return to the bond market with a $9 billion financing across four tranches featuring maturities ranging from two to 30 years. The deal is the largest pharmaceutical trade ever and the largest dollar-denominated corporate bond since 2001. It was led by Citigroup, JPMorgan and Lehman Brothers.

While GSK had been absent from the market since 2004, conferring considerable rarity value on the issue, it had to contend with recent competition from several

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options


Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here